Target Name: H19
NCBI ID: G283120
Review Report on H19 Target / Biomarker Content of Review Report on H19 Target / Biomarker
H19
Other Name(s): H19 imprinted maternally expressed transcript, transcript variant 1 | NCRNA00008 | WT2 | ASM | H19 variant 3 | D11S813E | ASM1 | MGC4485 | H19 imprinted maternally expressed transcript | LINC00008 | H19 variant 1 | BWS | MIR675HG | PRO2605 | H19 untranslated RNA | H19 imprinted maternally expressed transcript, transcript variant 3

H19: A Potential Drug Target Or Biomarker for Various Diseases

H19 (H19 imprinted maternally expressed transcript, transcript variant 1) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The H19 gene is located on chromosome 6 and is responsible for the production of a protein known as H19N, which is a key regulator of cell growth and differentiation. H19N plays a crucial role in ensuring that cells maintain a normal size and that they divide in a controlled manner, which is essential for the development and maintenance of tissues and organs.

Studies have shown that H19N is often expressed at high levels in a variety of tissues and organs, including brain, spinal cord, and pancreas, which suggests that it may be a promising biomarker for these diseases. In addition, H19N has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which further supports its potential as a drug target.

Another promising aspect of the H19 gene is its potential as a cancer drug target. Many cancer treatments, such as chemotherapy and targeted therapies, work by targeting and destroying cells that are abnormal or cancerous. H19N is a key regulator of cell growth and differentiation, which suggests that it may be a useful target for cancer therapies.

In addition to its potential as a drug target, H19 has also been shown to be a potential biomarker for a variety of diseases. For example, H19N has been shown to be elevated in the brains of patients with Alzheimer's disease, which suggests that it may be a useful diagnostic tool for this disease. Similarly, H19N has been shown to be elevated in the blood of patients with Parkinson's disease, which suggests that it may be a useful biomarker for this disease.

Another application of the H19 gene is its potential as a therapeutic target for autoimmune disorders. Many autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, involve an overactive immune system that attacks the body's own tissues. H19N is involved in the regulation of immune cell function and has been shown to play a role in the development and progression of autoimmune disorders.

In conclusion, H19 (H19 imprinted maternally expressed transcript, transcript variant 1) is a gene that has a wide range of potential applications as a drug target or biomarker for a variety of diseases. Its involvement in the regulation of cell growth and differentiation, as well as its potential as a cancer and autoimmune disorder drug target, makes it an attractive target for further research and development.

Protein Name: H19 Imprinted Maternally Expressed Transcript

The "H19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about H19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15 | H4C16 | H4C2 | H4C3 | H4C4 | H4C5 | H4C6 | H4C7 | H4C8 | H4C9 | H6PD | HAAO | HABP2 | HABP4 | HACD1 | HACD2